Recent preclinical studies indicate that autophagy inhibition with HER2-targeted inhibitors may enhance tumor cell death in breast cancer cells as autophagy impairment restores sensitivity to HER2 inhibitors in breast cancer and in lapatinib-resistant EAC cell line (HER2-amplified esophageal adenocarcinoma) [131,132,133]. Here, ERBB2 is linked to breast carcinoma.